CoChat

Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis

Open access
Chen, Wenci, Pan, Xianjuan, Ji, Jing, Wu, Zhenhua, Lin, Xinxin · 2026 · Frontiers in Nutrition

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 4 of the 5 sources its claims cite were checked for support.

Abstract

Background Clostridioides difficile infection (CDI) is a significant healthcare-associated infection. Probiotics have been proposed as a preventive strategy. This umbrella review synthesizes evidence from meta-analyses on the efficacy of probiotics in preventing CDI. Methods A comprehensive systematic search was conducted in PubMed, Scopus, Web of Science, Embase, and the Cochrane Library up to December 2025. To manage overlap, a single primary systematic review was selected per outcome. The methodological quality of included reviews was assessed using AMSTAR-2, and the certainty of evidence was graded. Pooled effect sizes were calculated using a random-effects model. Results Sixteen systematic reviews and meta-analyses were included. The pooled relative risk (RR) from primary reviews indicated that probiotics significantly reduced CDI risk (RR = 0.37; 95% CI: 0.32 to 0.42; I 2 = 0%). Multi-strain probiotics and formulations containing Saccharomyces boulardii showed significant benefits. The quality of evidence ranged from moderate to low, and overlap among primary studies was minimal (Corrected Covered Area = 15%). Conclusion Probiotic supplementation is associated with a reduced risk of CDI. However, given the variable methodological quality of the underlying evidence, these findings should be interpreted with caution. Population-specific and strain-specific effects require further investigation.

Overview

CoChat Summary

## TL;DR

This umbrella review found that probiotic supplementation was associated with a lower risk of Clostridioides difficile infection (CDI), with the main pooled estimate showing RR = 0.37 (95% CI 0.32 to 0.42). The strongest signals were for Saccharomyces boulardii and multi-strain formulations, but the underlying evidence was mostly low quality.

## Key findings

  • Sixteen systematic reviews and meta-analyses were included; overlap among primary studies was minimal (Corrected Covered Area = 15%).
  • In the primary RR synthesis based on seven meta-analyses, probiotics reduced CDI risk by 63%: RR = 0.37 (95% CI 0.32 to 0.42; p < 0.001; I2 = 0%).
  • Subgroup results showed significant benefits for Saccharomyces boulardii (RR = 0.38; 95% CI 0.27 to 0.53; 3 reviews) and multi-strain formulations (RR = 0.34; 95% CI 0.24 to 0.49; 4 reviews).
  • The OR synthesis from four meta-analyses also favored probiotics: OR = 0.54 (95% CI 0.32 to 0.89; p = 0.001), though heterogeneity was substantial (I2 = 74.9%).

## Methods

  • Umbrella review of systematic reviews and meta-analyses, conducted per PRISMA 2020 and registered in PROSPERO (CRD420251062730).
  • Searched PubMed, Scopus, Web of Science, Embase, and the Cochrane Library from inception through December 2025; English-language studies only.
  • Included systematic reviews/meta-analyses of probiotics for CDI prevention that reported effect sizes and confidence intervals; quality assessed with AMSTAR-2, certainty with GRADE, overlap with CCA, and pooled effects estimated using random-effects REML models.

## Limitations

  • Stated by the paper: 11 of 16 included reviews were rated “critically low” on AMSTAR-2; overall certainty of evidence was “low” by GRADE.
  • Stated by the paper: robust quantitative analyses could not be performed for all pre-specified strata, including specific dosage and patient sub-populations, because of inconsistent reporting in the source reviews.
  • Evident from the text: the evidence combines diverse probiotic strains and populations, and some results rely on only a few meta-analyses, which limits strain-specific and population-specific conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fnut.2026.1699223

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 PRISMA flow diagram.
Figure 1 PRISMA flow diagram.CC BY · PubMed Central
Figure 2 Effect size and 95% CIs presented in forest plot of the studies on the probiotics supplementation in CDI prevention based on RR analysis. Weights are from random-effects model.
Figure 2 Effect size and 95% CIs presented in forest plot of the studies on the probiotics supplementation in CDI prevention based on RR analysis. Weights are from random-effects model.CC BY · PubMed Central
Figure 3 Effect size and 95% CIs presented in forest plot of the studies on the probiotics supplementation in CDI prevention based on OR analysis. Weights are from random-effects model.
Figure 3 Effect size and 95% CIs presented in forest plot of the studies on the probiotics supplementation in CDI prevention based on OR analysis. Weights are from random-effects model.CC BY · PubMed Central

Verification

Claims the paper makes

3 Valid · 0 Not valid · 0 Not checked · 29 Own results and interpretations

11 more claims

Create a free account to see all 32 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 12
  • It may state two separate claims as one. 4

Create a free account to see these claims.

Citations

Cites

Research works printed but not linked: 1

  1. Pattani, 2013, Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis, Open Med., 7, e56

Cited by

See all 3

Metadata

Authors
Chen, W., Pan, X., Ji, J., Wu, Z., & Lin, X.
Affiliations
  • Zhejiang Chinese Medical University (CN)
  • Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
  • Department of Rehabilitation, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine
Corresponding author
  • Ji, Jing
  • Wu, Zhenhua
  • Lin, Xinxin
Venue
Frontiers in Nutrition
Published
2026-03-09
Volume
13
Pages
1699223-1699223
ISSN
2296-861X (ISSN-L)
OpenAlex
W7134243021
Cited by
3
References
41
Citations by year
2026: 3
FWCI
4.18
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Nutrition (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Science and Technology Plan Project of Wenzhou, China
  • Natural Science Foundation of Zhejiang Province (LQ24H270001)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
probiotics, Clostridium difficile infection, infection control, nosocomial infections, Saccharomyces boulardii, multi-strain probiotics, probiotic formulation, probiotic supplementation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.